Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMed

Isoquercitrin-loaded adipose-derived stem cell exosomes synchronize immunomodulation and neurovascular remodeling to accelerate spinal cord regeneration.

Xia W., Liu S., Gao T., Xue F., Guo Q., Lou Z.

Animal Study on Spinal Cord Injury, Neuroinflammation, Chronic Inflammation, Immune Modulation, published in Int J Pharm (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Int J Pharm (2026)
Country
Netherlands
Reported sample size
—
Source database
PubMed
PMID
42285382
DOI
10.1016/j.ijpharm.2026.127072

Abstract (original English)

Spinal cord injury (SCI) involves complex and interconnected pathological processes, including microglia-driven inflammation, vascular disruption, and impaired neuronal metabolic homeostasis, which collectively limit functional recovery. Here, we developed an isoquercitrin-loaded adipose-derived stem cell exosomes formulation (IQC@ADSCs-EXOs) as a natural nanocarrier delivery platform to coordinately modulate key cellular components within the lesion niche. IQC@ADSCs-EXOs exhibited typical vesicular morphology with nanoscale size distribution and a negative surface potential, and were efficiently internalized by microglia, endothelial cells (ECs), and neurons. Functionally, IQC@ADSCs-EXOs attenuated myelin debris-induced lipid droplet accumulation, lipid peroxidation, and intracellular ROS in BV2 cells, accompanied by a shift toward an anti-inflammatory phenotype. Meanwhile, IQC@ADSCs-EXOs promoted endothelial proliferation, migration, and tube formation, and enhanced mitochondrial activity with increased neurite outgrowth in PC12 cells. In a mouse contusive SCI model, local administration of IQC@ADSCs-EXOs was associated with improved vascular rebuilding, reduced neuroinflammation, enhanced axonal regeneration, and better locomotor and electrophysiological outcomes compared with controls. Collectively, these findings support IQC@ADSCs-EXOs as a nanotherapeutic platform with mu

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
AnimalsExosomesQuercetinMiceSpinal Cord InjuriesAdipose TissueStem CellsNerve RegenerationRatsPC12 Cells

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research